Compare Amphastar Pharmaceuticals Inc (AMPH) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs ProShares Ultra QQQ ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while ProShares Ultra QQQ ETF trades at $91.19. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QLD | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $30.81 | $100.53 |
52-Week Low | $16.87 | $57.16 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
QLD, the ProShares Ultra QQQ ETF, trades at $92.2, up 2.3% today, reflecting strong bullish momentum. Technical indicators show a bullish moving average consensus and key support at $91, with resistance at $93. Recent institutional buying, including a 29.4% stake increase by 180 Wealth Advisors in Q2 2026, underscores confidence. The ETF has delivered over 10,000% total return since inception, though its leveraged structure amplifies volatility.
The outlook for QLD is cautiously optimistic, driven by tech sector strength and tactical ETF demand. However, risks include amplified losses during market downturns, with a historical maximum drawdown of 63.80%. Investors should weigh the potential for outsized gains against the inherent volatility of daily leveraged products in a shifting economic landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
